Membrane Topology of an ATP-gated Ion Channel (P2X Receptor)*

Alison NewboltDagger , Ron Stoop§, Caterina Virginio, Annmarie Surprenantparallel , R. Alan Northparallel , Gary Buell, and François Rassendren**

From the Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, Plan-les-Ouates, 1228 Geneva, Switzerland

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Western blots of Xenopus oocyte membrane preparations showed that the apparent molecular mass of the wild type P2X2 receptor (about 65 kDa) was reduced by pretreatment with endoglycosidase H. Mutagenesis of one or more of three potential asparagines (N182S, N239S, and N298S) followed by Western blots showed that each of the sites was glycosylated in the wild type receptor. Functional channels were formed by receptors lacking any single asparagine, but not by channels mutated in two or three positions. Artificial consensus sequences (N-X-S/T) introduced into the N-terminal region (asparagine at position 9, 16, or 26) were not glycosylated. Asparagines were glycosylated when introduced at the C-terminal end of the first hydrophobic domain (positions 62 and 66) and at the N-terminal end of the second hydrophobic domain (position 324). A protein in which the C terminus of one P2X2 subunit was joined to the N terminus of a second P2X2 subunit (from a concatenated cDNA) had twice the molecular mass of the P2X2 receptor subunit, and formed fully functional channels. The experiments provide direct evidence for the topology originally proposed for the P2X receptor, with intracellular N and C termini, two membrane-spanning domains, and a large extracellular loop.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The extracellular signaling properties of nucleotides are mediated through two distinct families of membrane proteins. These are the P2Y receptors, coupled to G proteins and second messenger pathways, and the P2X receptors, which are ligand-gated ion channels (1). Seven subunits of the P2X receptor family (P2X1-7) have been characterized at the molecular level (reviewed in Refs. 2 and 3). These show a broad expression pattern compared with other ligand-gated channels, with the various forms being found in central and peripheral nervous system, different types of immune cells, glands, and smooth and skeletal muscles (4). The P2X receptor subunits can form channels as homomultimers or, in some cases, as heteromultimers (5, 6). The number of subunits in each channel molecule is not known.

P2X receptor subunits are 36-48% identical to one another at the amino acid level. All seven proteins have similar hydrophobicity profiles, with only two hydrophobic regions sufficiently long to span the plasma membrane. These regions display the features often seen in transmembrane segments such as aromatic residues at interfacial regions, and they have an excess of positively charged amino acids at their presumed cytoplasmic ends (7). Together with the absence of signal peptide sequence after the initiating methionine, this suggests that P2X receptors may have intracellular N and C termini, and two transmembrane domains separated by a large extracellular loop (8, 9). This proposed topology differs from that of the nicotinic and glutamate superfamilies of ligand-gated ion channels (reviewed in Ref. 10), but resembles that shown for the pore-forming subunits of epithelial sodium channels (11, 12). There is, however, no detectable similarity of amino acid sequence between P2X receptors and epithelial sodium channels (3).

There are other experimental results that are consistent with this topological model of P2X receptor subunit. First, P2X1 receptors are activated by the ATP analog alpha beta meATP,1 whereas P2X2 receptors are not; transferring the putative extracellular loop (approximately residues 50-320) from the P2X1 receptor into the P2X2 receptor confers alpha beta meATP sensitivity (13). Second, changing one amino acid within the loop of the P2X4 receptor (E249K) causes a large increase in the blocking action of the slowly reversible antagonist pyridoxal-5-phosphate-6-azophenyl-2'-4'-disulfonic acid (14). Third, the difference in sensitivity to pyridoxal-5-phosphate-6-azophenyl-2'-4'-disulfonic acid between human and rat P2X4 receptors can be transferred by exchange of a segment within the first half of this loop (15). Fourth, evidence for N-glycosylation of Asn184 of the P2X1 receptor has been obtained, indicating that this must be located extracellularly (16).

The recent identification of residues contributing to the pore of the P2X2 receptor has also provided evidence for an intracellular location for the C-terminal part of the protein (17). Amino acids in and around the second hydrophobic domain of the P2X2 receptor (residues 316-354) were mutated individually to cysteine, the proteins were expressed, and ATP-activated currents were measured. Inhibition of the current by polar methanethiosulfonate derivatives was then used to determine whether the residue was likely exposed to the aqueous solution. One substitution was identified (D349C) at which extracellularly applied methanethiosulfonate ethylamine inhibited the ATP-evoked current. However, the inhibition required channel opening. Because methanethiosulfonate ethylamine can permeate the open channel, these results indicate that Asp349 normally lies internal to the channel "gate." The residue is close to the C-terminal end of the second hydrophobic region; this therefore implies that the C terminus of the protein is within the cytoplasm, because there is no further hydrophobic domain long enough to span the plasma membrane.

These results are consistent with the topology for P2X receptors initially proposed (8, 9), but alternative models are also possible. For example, the data generated so far on cloned P2X receptors might as well be explained with a model in which only the second hydrophobic domain spans the plasma membrane, placing the entire N-terminal part of the protein extracellularly. Therefore, we have used the N-glycosylation site tagging approach to determine the precise topology of P2X2 receptors. During protein biosynthesis, extracellular domains of the protein are facing the lumen of the endoplasmic reticulum where they are able to be glycosylated. Due to the strict compartmentalization of N-glycosylating enzymes at the luminal face of the endoplasmic reticulum, it is possible to assess the extracellular location of different region of a given protein by N-glycosylation site tagging. This approach has been used to determine the topology of other membrane proteins including channels and transporters (18, 19).

We first identified the endogenous N-glycosylation of P2X2 receptor, and then by mutagenesis obtained a form in which no natural N-glycosylation of the protein remained. The cDNA for this modified form of the receptor was then used as a background plasmid to engineer artificial N-glycosylation sites at different locations in the protein, with respect to the two hydrophobic domains. The extent of N-glycosylation was assayed by gel shift assay after functional expression of epitope-tagged forms of the P2X2 receptor in Xenopus oocytes. Finally, we concatenated cDNAs and expressed the tandem constructs to show that the N and C termini reside on the same side of the plasma membrane.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Mutagenesis-- In all experiments, a P2X2 receptor cDNA was used that carried a C-terminal epitope (DPGLNEYMPME), cloned into the expression vector pcDNA3 (Invitrogen) (17, 20). Point mutations in P2X2 receptor cDNA were introduced by full-length polymerase chain reaction amplification of plasmid DNA with sense and antisense mutated primers. Pfu polymerase (Stratagene) was used to reduce the rate of contaminating mutations. Parental (wild type) DNA was digested with 10 units of DpnI (New England Biolabs) for 1 h at 37 °C; 2.5 µl of the reaction was then directly used for transformation of Escherichia coli DH5alpha strain. DNA fragments carrying the mutation were digested with appropriate restriction enzymes and subcloned in a background vector that had not been amplified. All mutants were sequenced on both strands.

Construction of Dimeric cDNAs-- A concatenated tandem P2X2 receptor cDNA was constructed in pBluescript vector. Briefly, two P2X2 cDNAs were modified by in-frame addition of an EcoRI site either at the 5' or 3' end of the coding sequence, respectively. These two cDNAs were ligated through the EcoRI site and a unique site from the backbone of the vector. The resulting construct contains two P2X2 subunits linked from the C terminus of one (-KGLAQL) to the N terminus of another (MVRRLA-); the deduced amino acid sequence at the junction site is -KGLGIRLA-. The mutant subunit P2X2-T336C (17) was also constructed in pcDNA3; it also had the C terminus tag. To create the wild type-mutant dimer, a fragment from the Bluescript dimer was obtained by BstEII digestion and subcloned into the BstEII site of P2X2-T336C. The resulting plasmid encodes a wild type subunit followed by a mutant subunit and has the C-terminal epitope tag.

Gel Shift Assay-- Stage V-VI oocytes were removed from ovaries of anesthetized Xenopus laevis as described (21). Ovarian lobules were treated with 1 mg/ml collagenase (Sigma) for 2 h at room temperature in calcium-free solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM sodium pyruvate, 5 mM Hepes, 10 units/ml penicillin, and 10 units/ml streptomycin). Healthy oocytes were selected and allowed to recover overnight prior to injection. Plasmid DNA was directly injected into oocyte nuclei. All plasmids were co-injected with an enhanced green fluorescent protein (EGFP)-containing plasmid (pEGFP, Life Technologies, Inc.). From 24 to 48 h after injection, EGFP-positive oocytes were sorted using a fluorescent microscope. Crude membrane fractions were prepared from batches of 12 oocytes; oocytes were homogenized in 240 µl of buffer H (100 mM NaCl, 20 mM Tris-HCl (pH 7.4), 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 20 µg/ml benzamidine hydrochloride, 200 µg/ml pepstatin A, 250 µg/ml aprotinin, 260 µg/ml alpha 1-antitrypsin, 100 ng/ml soybean trypsin inhibitor, 200 µg/ml bestatin). Homogenates were shaken for 15 min at 4 °C and centrifuged at 14,000 × g for 2 min. After denaturation, membrane-containing supernatants were separated by SDS-polyacrylamide gel electrophoresis on a 8% Tris glycine gel (Novex). Separated proteins were electro-transferred onto nitrocellulose membranes (2 h, 25 V, 4 °C). Membranes were blocked with 5% milk, 0.2% Tween 20 in phosphate-buffered saline for 1 h at 37 °C. Monoclonal antibody against EYMPME (22) was added at 1:1000 dilution and incubated for 16 h at 4 °C, in 2.5% milk, phosphate-buffered saline solution. A secondary antibody (goat anti-mouse IgG) conjugated to horseradish peroxidase was added at a 1:1000 dilution in 2.5% milk and incubated for 1 h at 37 °C. Proteins were detected by a chemiluminescent assay (ECL detection kit, Amersham Pharmacia Biotech).

Endoglycosidase H Treatment-- Membrane extracts (15 µl) were incubated with 10 µl of endoglycosidase H for 1 h at 37 °C in the presence of 0.2% SDS and 0.4% 2-beta -mercaptoethanol.

HEK Cell Transfection, Electrophysiological Recording, and Immunocytochemistry-- Transfection of human embryonic kidney 293 (HEK) cells, and electrophysiological recording from oocytes and HEK cells has been described previously (17, 21). HEK cells were co-transfected with EGFP cDNA (0.5 µg/ml; CLONTECH) and the relevant P2X2 receptor cDNA (1 µg/ml), and recordings were made 18-48 h later. All EGFPpositive (i.e. fluorescent) cells exhibited ATP-evoked current.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Identification of Natural N-Glycosylation-- We determined if it was possible to detect tagged P2X2 protein by Western blot from a crude oocyte membrane preparation. As shown in Fig. 1, when oocytes were injected with the wild type P2X2 cDNA, the anti-EE antibody recognized a protein of apparent molecular mass around 65 kDa. The calculated size of the P2X2 receptor protein is 52.6 kDa; the observed difference is due to N-glycosylation because a mutated subunit lacking all three asparagines found at consensus glycosylation sites (N-X-S/T) migrated at approximately 50 kDa. The broad smear of the wild type Western blot may result from the fact that crude membrane preparations were used; these would include not only plasma membrane but also the membrane of intracellular organelles (endoplasmic reticulum and Golgi) in which the identity and length of sugars added to proteins might be variable. Uninjected or EGFP-injected oocytes showed no staining or very weak bands (Fig. 1B).


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   Native N-glycosylation of the P2X2 receptor. A, model of P2X2 receptor indicating three Asn residues within N-X-S/T consensus sites. B, control immunoblot of membranes from oocytes expressing wild type (WT) P2X2 receptor and GFP, Delta 3N-P2X2 receptor and GFP, nothing (uninjected), or GFP alone. Arrowheads indicate nonspecific binding of the antibody. C, characterization of native N-glycosylation sites by gel shift assay. Sites were removed by mutagenesis singly (N182S, N239S, N298S), doubly (N182S/N239S, N182S/N298S, N239S/N298S) or triply (N182S/N239S/N298S: Delta 3N). Note the progressive reduction in the apparent molecular mass of the protein as the number of N-glycosylation sites decreases. D, in wild type and doubly mutant proteins, Endo H causes a reduction in the apparent molecular mass to that of the Delta 3N-P2X2 receptor. Note that, under these conditions, Endo H does not completely deglycosylate the wild type P2X2 receptor.

The P2X2 receptor primary sequence contains three consensus sites for N-glycosylation (N-X-S/T); these are Asn182, Asn239, and Asn298. To determine if any or all of these were glycosylated, we constructed a series of mutants in which one, two, or three sites were removed. As shown in Fig. 1 (C and D), all three sites were glycosylated in Xenopus oocytes. This was evidenced by the progressive reduction of the apparent molecular mass of P2X2 protein as the number of N-glycosylation sites decreases (Fig. 1C). No differences were obvious among the three single mutants (N182S, N239S, and N298S) or among the three double mutants (N182S/N239S, N182S/N298S, and N239S/N298S), suggesting that all three asparagines are modified (Fig. 1C). This was further demonstrated by the effect of endoglycosidase H (Endo H). Membrane preparations of oocytes expressing wild type P2X2 receptors and the three double mutants were treated with Endo H; in each case, this led to the appearance of a band that co-migrated with the triply mutant receptor (Delta 3N-P2X2) (Fig. 1D). A fraction of the protein in each case was resistant to Endo H; this may be because Endo H only hydrolyzes high mannose oligosaccharides specific to the endoplasmic reticulum and does not affect sugars added in other compartments such as the Golgi. Higher concentrations of enzyme or longer incubation times did not change the pattern of action of Endo H. In the case of the Delta 3N-P2X2 receptor, Endo H had no effect on the apparent molecular mass of the protein (data not shown).

Mutants lacking one, two, or three N-glycosylation sites were transfected in HEK293 cell and tested electrophysiologically for the presence of ATP-induced currents. In HEK293 cells expressing each of the single mutants, ATP (30 µM) evoked inward currents that were not obviously different from those observed in cells expressing wild type receptors (Fig. 2). These results indicate both that full glycosylation is not required for normal function, and that the point mutations introduced do not critically disrupt the overall structure of the protein. However, in cells expressing the double mutations ATP evoked only very small currents, and on the triple mutant receptor (Delta 3N-P2X2) ATP had no detectable effect.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Functional P2X receptors may lack one N-linked glycan. A, examples of currents evoked by ATP (30 or 300 µM) in HEK293 cells transfected with the indicated P2X2 receptor. B, histogram of amplitude of currents evoked by maximum ATP concentrations in cells transfected with the indicated cDNAs. Currents evoked by ATP were normal in cells expressing receptors with any single asparagine mutated; however, currents were greatly reduced or absent in cells transfected with constructs in which more than one asparagine was mutated. WT, wild type.

Introduction of Artificial N-Linked Glycosylation Sites-- We introduced three point mutations resulting in consensus sites for N-glycosylation into the Delta 3N-P2X2 receptor between the initiating methionine and the beginning of the first hydrophobic regions (C9N, Y16N, and R28T) (Fig. 3A). Fig. 3B shows that the protein had the same apparent molecular weight as Delta 3N-P2X2, indicating that this N-terminal region is not accessible to the glycosylating enzymes. Thus, this experiment failed to provide any evidence for an extracellular location of the N terminus.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3.   Consensus N-linked glycosylation sites introduced into the N terminus are not used. A, model to show position of mutations made (in Delta 3N-P2X2 receptor). B, Western blot shows that the protein with three potential glycoslyation sites introduced (C9N/Y16N/R28T in Delta 3N-P2X2) has the same apparent molecular mass as Delta 3N-P2X2. WT, wild type.

The Delta 3N-P2X2 receptor was next used as a background construct to insert mutations at the extracellular aspects of the putative transmembrane regions, as deduced from the hydrophobicity plots. In the first experiments, five asparagines were individually introduced close to the end of the first hydrophobic domain (Fig. 4A) (Q52N, Q56N, S58N, P62N, and I66N). Two of these (P62N and I66N) had a higher molecular weight than Delta 3N-P2X2; two bands were seen in the case of the P62N mutant, one corresponding to Delta 3N-P2X2 and one at the same position as that seen with I66N. The size of the mobility shift corresponded to that expected from a single glycosylation, and for both P62N and I66N the shift could be prevented by pre-incubation of the membrane preparation with Endo H (Fig. 4C).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Defining the outer membrane boundary of the first hydrophobic domain. A, model to show position of mutations made (in Delta 3N-P2X2 receptor). B, Western blot shows that two of the five mutations (P62N and I66N) result in proteins with higher apparent molecular masses than the Delta 3N-P2X2 receptor. P62N is partially modified. C, the difference in molecular mass results from glycosylation because it is inhibited by pretreatment with Endo H. D, no evidence for glycosylation was observed in Q52N and Q56N, even when further mutations were introduced which might optimize the N-glycosylation sequence. WT, wild type.

The lack of N-glycosylation observed at position Q52N, Q56N and S58N might result from suboptimal consensus sequences (N-K-S, N-D-S, and N-E-T, respectively). The sequence N-F-T was therefore introduced at these positions, because this occurs at two of the three naturally occurring sites in the P2X2 receptor. However, these mutant receptors were also not glycosylated (Fig. 4D). This suggests either that this portion of the protein lies too close to the plasma membrane (23) or that N-glycosylation is prevented for other structural reasons. We introduced the same mutations into the P2X2 receptor in which the three naturally occurring sites were left intact, and we tested for expression electrophysiologically in HEK293 cells. Q52N, S58N, and P62N gave apparently normal currents in response to ATP, whereas cells transfected with the Q56N and I66N forms did not respond to ATP. The lack of response to ATP with I66N could be accounted for by the structural change resulting from Asn in place of Ile, or it could be because the attached sugar moiety prevents receptor function (e.g. ATP binding). The latter possibility is favored by the observations that I66S, I66L, and I66C all provided functional channels with normal responses to ATP (currents were 3.6 ± 0.7 nA, 3.9 ± 0.4 nA, and 4.1 ± 0.6 nA, respectively; n = 6 in each case).

Close to the second hydrophobic domain, the mutations K324N, I328N, and A335T were made so as to introduce consensus sequences N-F-S, N-P-T, and N-L-T (Fig. 5). Only K324N displayed a shift in mobility; as for P62N, two bands were seen, with one migrating at the same size as the Delta 3N-P2X2 receptor (Fig. 5B). The higher molecular weight band resulted from a glycosylated receptor because it was abolished by preincubation of the membrane preparation with Endo H (Fig. 5C). The lack of glycosylation of I328N might reflect the introduction of the sequence N-P-T; it has been previously shown that a proline at position X in the consensus sequence N-X-T/S strongly reduces the likelihood of N-glycosylation (24). We made the double mutant I328N/P329F, which creates the sequence N-F-T. This was also not glycosylated, but a shorter form of the protein was consistently observed (Fig. 5D). When the double mutation I328N/P329F was introduced in the P2X2 receptor, which carried the three native glycosylation sites, no functional expression was obtained (data not shown). However, the mutation A335T in this "wild type" background resulted in apparently normal responses to ATP.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5.   Defining the outer membrane boundary of the second hydrophobic domain. A, model to show position of the mutations made (in Delta 3N-P2X2 receptor). B, Western blot shows that one of the three mutations (K324N) results in a protein with higher apparent molecular mass than the Delta 3N-P2X2 receptor. K324N is partially modified. C, the modification of K324N results from glycosylation because it is inhibited by pretreatment with Endo H. D, no evidence for glycosylation was observed in I328N, even when a further mutation was introduced (P329F) that might optimize the N-glycosylation sequence. Note the lower apparent molecular mass of the I328N/P329F protein (arrowhead). WT, wild type.

Expression of Dimeric cDNAs-- The failure to observe glycosylation when consensus sequences were introduced into the region N terminus to the first hydrophobic domain is unhelpful with respect to assignment of this domain to one or other side of the membrane, because not all consensus sites are used (24). We therefore sought to determine whether the N and C termini were located on the same side of the membrane by expressing a concatenated cDNA (25). Fig. 6B shows a Western blot from oocytes injected with the dimeric construct. A single band was observed at a molecular mass of about 120 kDa, indicating that the intact dimeric protein is expressed. Recordings made from the same oocytes, prior to membrane preparation for Western blotting, showed inward currents evoked by ATP (30 µM) which were not obviously different from those seen in oocytes expressing the monomeric wild type protein (data not shown). We have previously shown that substitution of Cys for Thr at position 336 in the P2X2 receptor produces a channel in which methanethiosulfonate ethyltrimethylammonium (MTSET) almost completely blocks the current evoked by ATP (17). MTSET inhibited the currents by about 50% when the Cys to Thr substitution was made in either the first or second (Fig. 6C) domain of the dimeric construct, and by close to 100% when the mutation was in both domains (25).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   Both domains of a dimeric concatenated receptor contribute to pore formation. A, model to show position of mutation made (corresponds to T336C in second domain of dimerized wild type P2X2 receptor). B, Western blot from oocytes expressing monomeric and concatenated dimeric P2X2 cDNAs. In the latter case, the protein has an apparent molecular mass close to 120 kDa; no evidence of degraded monomeric forms is observed. C, ATP evokes inward currents from oocytes injected with the concatenated dimeric P2X2 cDNA. Superimposed traces are currents evoked by ATP (100 µM) applied for 30 s (horizontal bar), at intervals of 4 min before (CONTROL) or after (MTSET) adding MTSET (1 mM).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

These experiments show that the P2X2 receptor is a glycoprotein, in which all three consensus sequences for N-linked glycosylation (N-X-S/T) are used. Among the seven P2X receptor subunits, the number of such consensus sequences ranges from three (P2X2, P2X5, P2X6) to seven (P2X4), and in no case is the consensus sequence found at a corresponding position in all seven sequences. However, the sequence around Asn182 of the P2X2 receptor (N-F-T) is present in all except the P2X5 receptor, and it is also found within a region of the protein showing relatively high homology among all seven subunits. This suggests that it may be glycosylated in them all (except P2X5); indeed, the corresponding residue in the P2X1 receptor provides the only previously known glycosylation site in the P2X receptor family (16). Our finding that fully functional ATP-gated channels are found with the point mutation N182S is consistent with the inference from the P2X5 receptor sequence that glycosylation at this position is not essential for channel assembly and function.

The second of the two sites identified in the present study (Asn239 of N-F-T) also occurs in a relatively highly conserved region of the protein, but in this case the consensus sequence is found only in the P2X2 and P2X7 receptors. The third of the three sites found to be glycosylated is the Asn298 of N-G-T; the consensus sequence is found at this position also in the P2X1 and P2X3 receptors but not in the other receptors. A further conserved consensus site that is missing in the P2X2 receptor is found in receptors P2X4-7 (corresponding to Asn255 in the P2X4 receptor), and it will be interesting to determine whether this is also glycosylated.

We found that the currents induced by ATP in HEK293 cells expressing P2X2 receptors lacking any one of the three asparagines were essentially normal (Fig. 2), suggesting that none of the attached sugars play a significant role in agonist recognition and binding. On the other hand, receptors in which two or three asparagines were substituted by serine responded to ATP either very poorly or not at all (Fig. 2). We have visualized the cells immunohistochemically using standard fluorescent or confocal laser microscopy: all showed a pattern of plasma membrane localization similar to that seen in the wild type, but the fluorescence intensity was significantly reduced in the receptors lacking two or three (but not one) glycosylation sites.2 This finding implies that full glycosylation is not necessary for correct protein folding and transport to the plasma membrane. However, further immunohistochemical studies of these receptors tagged in the extracellular domain would be useful to examine whether the unglycosylated protein is correctly inserted in the plasma membrane.

The main aim of the present work was to delineate the boundaries of the putative transmembrane domains. We interpret the finding of glycosylation at residues P62N, I66N, and K324N to indicate that these positions are exposed at the extracellular aspect of the membrane; Pro62 is the 11th amino acid residue following the final hydrophobic residue of the first hydrophobic domain (Val51). The failure to observe glycosylation at sites closer to the hydrophobic domain (Q52N, Q56N, and S58N) might be because they are situated within the interfacial region and inaccessible to glycosylating enzymes (23), or because these mutations prevent normal folding and membrane expression. The latter interpretation seems less likely in view of the finding of normal functional responses in the wild type P2X2 receptor carrying mutations Q52N, S58N, or P62N. The residues corresponding in position to Gln52, Ser58, and Pro62 are highly variable among the seven P2X receptor subunits, and may be presumed to tolerate asparagine. The lack of functional responses in the case of mutations Q56N and I66N indicates that these substitutions are not tolerated; the residues in these positions are identical (all glutamine) or highly conserved (six valine, one isoleucine) among the seven subunits. Altogether, the results are consistent with the interpretation that Q52N and S58N are not glycosylated because they are located too close to the plasma membrane, although other structural reasons can not be excluded.

The second hydrophobic domain probably begins with Ile331, although residues at positions 327 and 328 are conserved hydrophobic amino acids in all seven P2X receptor subunits. The present finding that K324N was glycosylated shows clearly that this position is located on the extracellular surface of the cell. In the P2X2 receptor in which the three native glycosylation sites were left intact, K324C functions normally and appears not to contribute to the ion permeation pathway (17). This Lys residue occurs within a completely conserved motif (G-X-X-G-K-F), which might be thought to resemble that observed in some ATP-binding proteins (26); the finding that Lys324 can be replaced by Cys without obvious change in function argues against any such critical role. In the case of Ile328, substitution by Cys results in a channel which is sensitive to block by MTSET (17). One interpretation of that result is that Ile328 is situated within the outer vestibule of the channel; such close proximity to the membrane could be the reason why no glycosylation was observed when asparagine was introduced at this position.

The failure to observe any glycosylation in the case of three engineered Asn residues in the region of the molecule preceding the first hydrophobic domain N terminus is consistent with an intracellular location for this segment. However, direct evidence that both the N and the C termini are located on the same aspect of the membrane was obtained by the construction and expression of a concatenated dimeric cDNA (25). Taken together with previous work, which suggested that the C terminus should be intracellular (17), these findings indicate that both N and C termini are located within the cell. The observation that the substitution T336C confers responsiveness to MTSET when introduced into either the first or second domain of concatenated subunits is consistent with both subunits of the dimer contributing to the pore (25). Further quantitative experiments on dimers, trimers, and larger multimers might be interpretable with respect to the channel stoichiometry and are presently in progress.

The main conclusion of the present work is that each subunit of the P2X2 receptor, and presumably the other homologous family members, has intracellular N and C termini, two hydrophobic domains (approximately residues 31-51 and 331-353), and a large extracellular loop (52-330). We cannot exclude the possibility that regions of this long loop fold back into the plasma membrane, although we note that any such regions that are predominately hydrophobic are only six or seven amino acids in length. The identification of the natural glycosylation sites indicates that residues 184, 239, and 298 are extracellular. This overall topology is thus similar to that described for the alpha  subunit of the epithelial sodium channels (11). The sequence homology between the epithelial sodium channels and the FMRFamide-activated (27) and proton-activated (28) channels makes it likely that these other ligand-gated channels share the same overall pattern of membrane insertion, with two transmembrane domains and a large, cysteine-rich extracellular loop. This contrasts clearly with the other large families of ligand-gated ion channels which have either three (glutamate family) or four (nicotinic acetylcholine family) membrane-spanning segments per subunit (see Ref. 10).

    ACKNOWLEDGEMENTS

We thank Kathryn Radford for advice on Western blotting, Danielle Estoppey for tissue culture, and Denis Fahmi for oocyte preparation and injection.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: School of Biological Sciences, University of Manchester, Manchester M13 9PT, United Kingdom.

§ Present address: Institute Biologie Cellulaire et Morphologie, University of Lausanne, CH1005 Lausanne, Switzerland.

Present address: Dept. of Pharmacology, Glaxo Wellcome Research and Development, 37135 Verona, Italy.

parallel Present address: Inst. of Molecular Physiology, University of Sheffield, Sheffield 510 2TN, United Kingdom.

** To whom correspondence should be addressed. Tel.: 41-22-706-9739; Fax: 41-22-794-6965; E-mail: rassendren{at}serono.com.

1 The abbreviations used are: alpha beta meATP, adenosine 5'-(alpha ,beta -methylene)triphosphate; Endo H, endoglycosidase H; MTSET, methanethiosulfonate trimethylammonium; EGFP, enhanced green fluorescent protein.

2 A. Newbolt, R. Stoop, C. Virginio, A. Surprenant, R. A. North, G. Buell, and F. Rassendren, unpublished observations.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. North, R. A., and Barnard, E. A. (1997) Curr. Opin. Neurobiol. 7, 346-357[CrossRef][Medline] [Order article via Infotrieve]
  2. Buell, G., Collo, G., and Rassendren, F. (1996) Eur. J. Neurosci. 8, 2221-2228[Medline] [Order article via Infotrieve]
  3. North, R. A. (1996) Curr. Opin. Cell Biol. 8, 474-483[CrossRef][Medline] [Order article via Infotrieve]
  4. Collo, G., North, R. A., Kawashima, E., Merlo-Pich, E., Neidhart, S., Surprenant, A., and Buell, G. (1996) J. Neurosci. 16, 2495-2507[Abstract]
  5. Lewis, C., Neidhart, S., Holy, C., North, R. A., Buell, G., and Surprenant, A. (1995) Nature 377, 432-434[CrossRef][Medline] [Order article via Infotrieve]
  6. Radford, K. M., Virginio, C., Surprenant, A., North, R. A., and Kawashima, E. (1997) J. Neurosci. 17, 6529-6533[Abstract/Free Full Text]
  7. Von Heijne, G., and Gavel, Y. (1988) Eur. J. Biochem. 97, 175-181[Abstract]
  8. Valera, S., Hussy, N., Evans, R. J., Adami, N., North, R. A., Surprenant, A., and Buell, G. (1994) Nature 371, 516-519[CrossRef][Medline] [Order article via Infotrieve]
  9. Brake, A. J., Wagenbach, M. J., and Julius, D. (1994) Nature 371, 519-523[CrossRef][Medline] [Order article via Infotrieve]
  10. Dani, J. A., and Mayer, M. L. (1995) Curr. Opin. Neurobiol. 5, 310-317[CrossRef][Medline] [Order article via Infotrieve]
  11. Canessa, C. M., Merillat, A. M., and Rossier, B. C. (1994) Am. J. Physiol. 267, 1682-1690
  12. Renard, S., Lingueglia, E., Voilley, N., Lazdunski, M., and Barbry, P. (1994) J. Biol. Chem. 269, 12981-12986[Abstract/Free Full Text]
  13. Werner, P., Seward, E. P., Buell, G. N., and North, R. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15485-15490[Abstract/Free Full Text]
  14. Buell, G., Lewis, C., Collo, G., North, R. A., and Surprenant, A. (1996) EMBO J. 15, 55-26[Abstract]
  15. Garcia-Guzman, M., Soto, F., Gomez-Hernandez, J. M., Lund, P.-E., and Stuhmer, W. (1997) Mol. Pharmacol. 51, 109-118[Abstract/Free Full Text]
  16. Valera, S., Talabot, F., Evans, R. J., Gos, A., Antoarakis, S. E., Morris, M. A., and Buell, G. (1995) Receptors Channels 3, 283-289[Medline] [Order article via Infotrieve]
  17. Rassendren, F., Buell, G., Newbolt, A., North, R. A., and Surprenant, A. (1997) EMBO J. 16, 3446-3454[Abstract/Free Full Text]
  18. Hollmann, M., Maron, C., and Heinemann, S. F. (1994) Neuron 13, 1331-1343[Medline] [Order article via Infotrieve]
  19. Bennett, E. R., and Kanner, B. I. (1997) J. Biol. Chem. 272, 1203-1210[Abstract/Free Full Text]
  20. Kawashima, E., Estoppey, D., Fahmi, D., Virginio, C., Rees, S., Surprenant, A., and North, R. A. (1998) Receptors Channels, in press
  21. Evans, R. J., Lewis, C., Buell, G., North, R. A., and Surprenant, A. (1995) Mol. Pharmacol. 48, 178-183[Abstract]
  22. Grussenmeyer, T., Scheidtmann, K. H., Hutchinson, M. A., Eckhart, W., and Walter, G. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 7952-7954[Abstract]
  23. Landolt-Marticorena, C., and Reithmeier, A. F. (1994) Biochem. J. 302, 253-260[Medline] [Order article via Infotrieve]
  24. Gavel, Y., and von Heijne, G. (1990) Protein Eng. 3, 433-442[Abstract]
  25. Stoop, R., Thomas, S. L., Buell, G., and North, R. A. (1997) Soc. Neurosci. Abstr. 23, 376
  26. Traut, T. W. (1994) Eur. J. Biochem. 222, 9-19[Abstract]
  27. Lingueglia, E., Champigny, G., Lazdunski, M., and Barbry, P. (1995) Nature 378, 730-733[CrossRef][Medline] [Order article via Infotrieve]
  28. Waldmann, R., Champigny, G., Bassilana, F., Heurteaux, C., and Lazdunski, M. (1997) Nature 386, 173-177[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.